002004 华邦健康
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入5,922,0420.91%11,594,59013,232,36612,431,12610,876,362
减:营业总成本5,370,6294.47%10,449,04411,557,13311,386,50610,041,053
    其中:营业成本3,747,6619.49%7,059,5247,874,0687,682,2576,421,314
               财务费用139,40722.82%230,777207,490438,928594,829
               资产减值损失(11,745)-1,442.67%(380,091)(560,356)(138,335)(47,049)
公允价值变动收益(169)-94.94%1,199(4,837)8,51610,258
投资收益(11,733)-131.77%7,521441,485300,009245,510
    其中:对联营企业和合营企业的投资收益(38,638)-245.22%(28,839)425,722239,099158,642
营业利润562,344-30.55%926,5111,645,0001,333,6411,194,862
利润总额554,221-30.31%892,3881,622,6961,281,2461,165,083
减:所得税费用130,012-12.64%215,456495,488361,042270,078
净利润424,209-34.37%676,9321,127,207920,205895,006
减:非控股权益110,686-57.31%374,810693,724252,395243,275
股东净利润313,523-19.02%302,122433,484667,809651,731

市场价值指针
每股收益 (元) *0.159-18.87%0.1530.2190.3370.330
每股派息 (元) *----0.2200.2200.2200.220
每股净资产 (元) *5.034-2.20%5.1045.1485.1064.864
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容